AHK-Cu: uses, evidence and status | Inside Your Peptides

compound file

The answer, first. A copper-binding tripeptide, alanyl-histidyl-lysine, first tested on hair follicles in 2007 and sold since as a scalp and skin ingredient. The strongest evidence is for topical peptides for wrinkles, graded C — small or open-label human only.

Independent 2026 meta-analysis of 19 randomised trials: pooled wrinkle effect mean difference 0.27, P=0.04, driven mainly by the oral subgroup at 1.5 ⁴.

No AHK-Cu arm in any of them. Every other use — hair growth, skin collagen and wrinkles, copper delivered into skin — grade D or E: animal or mechanism data with no controlled human outcome.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 4 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Topical peptides for wrinklesmeta-analysis of 19 RCTs · class-wide preclinical datagrade CIndependent 2026 meta-analysis of 19 randomised trials: pooled wrinkle effect mean difference 0.27, P=0.04, driven mainly by the oral subgroup at 1.5 ⁴. No AHK-Cu arm in any of them.

02Hair growthno trial · 1 ex vivo human follicle studygrade DAHK-Cu from picomolar to nanomolar lengthened excised human hair follicles in organ culture and increased dermal papilla cell proliferation ¹. Its reduction in apoptotic cells was not statistically significant ¹. One study.

03Skin collagen and wrinklesno trial · none for this moleculegrade DNo study has tested AHK-Cu on human skin for any endpoint. The copper-peptide collagen record belongs to GHK-Cu, in rat wound chambers and cultured fibroblasts ²³. An independent review calls that clinical absence surprising ¹².

04Copper delivered into skinno trial · 1 permeation studygrade DThe one permeation study on a copper tripeptide measured copper crossing skin at roughly five times the molar rate of the peptide ⁵. It tested GHK-Cu, not AHK-Cu, so the chelate may not arrive intact.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetAHK-Cu is a tripeptide chelating one copper ion, sharing the histidine-anchored coordination chemistry that holds copper in GHK-Cu ⁶.

2signalIn cultured dermal papilla cells it raised the Bcl-2 to Bax ratio and lowered cleaved caspase-3 and PARP ¹.

3effectFollicle elongation in organ culture and papilla proliferation. Copper alone also drives MMP-1 and interleukin-8 in dermal fibroblasts ¹⁷.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

AHK-Cu is proven for hair loss. One 2007 study, in cultured cells and excised follicles. No randomised trial on a living scalp exists in any indexed journal ¹.
AHK-Cu works because GHK-Cu works. GHK-Cu's own randomised facial trial was null on every objective endpoint. Sharing a copper site is not sharing evidence ⁸.
Copper peptides are inert on skin. Copper stimulates MMP-1 and interleukin-8 in dermal fibroblasts, and a biomarker study flagged skin toxicity for certain copper compounds ⁷⁹.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeTopical scalp serum or cosmetic cream. No published study used AHK-Cu by any other route, in any species.

formatAqueous serum, usually blended with GHK-Cu. Also sold as a lyophilised powder.

published dosesNo human dosing study exists. The only primary study used AHK-Cu at picomolar to nanomolar concentrations on excised follicles and cultured dermal papilla cells ¹. No concentration has been tested on an intact scalp in a controlled trial, and supplier use levels for the raw material are not standardised.

human pharmacokineticsNo human pharmacokinetic data published.

reported conventionsAs reported on hair-loss and skincare forums, 2012 to 2026: scalp serums somewhere around 0.05% to 0.2%, applied daily. Usually blended with GHK-Cu and often layered under minoxidil. Convention, not guidance.

commonly paired withGHK-Cu

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetNo trial has measured onset. The single primary study ran in organ culture and cell culture, never on a person ¹. As reported: three to six months before any change is claimed, tracking the hair cycle. No trial measured that.

most common reportAs reported: less shedding before any change in density. Many report nothing.

adverse effectsNo human safety trial exists for AHK-Cu at any concentration or route. As reported topically: scalp itch, stinging, transient discolouration. Copper compounds have been flagged for skin toxicity on selected biomarkers in cell work ⁹.

the stop signalAs reported: scalp irritation, or a full hair cycle passing with nothing to show. No published stopping rule exists for this molecule.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalNot approved anywhere. Sold as a cosmetic ingredient and as a research chemical.

FDANot named on FDA's 503A list of bulk substances presenting significant safety risks, checked 24 August 2026 ¹⁰.

sport [WADA]Not named. S0 catches any non-approved substance ¹¹.

sold asresearch chemical

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is AHK-Cu used for?

Hair growth, mostly, and it appears in some skin serums. The entire indexed primary record is one 2007 study from Seoul National University.

AHK-Cu lengthened excised human hair follicles in organ culture and made dermal papilla cells proliferate, at picomolar to nanomolar concentrations. That grades D, because organ culture is not a person. Nothing has tested AHK-Cu on a living scalp, and nothing has tested it on skin at all.

How is AHK-Cu used?

Descriptively, and labelled as such. There is no published human protocol, because there is no published human study. The one primary paper dosed excised follicles and cultured cells at picomolar to nanomolar concentrations.

As reported on hair-loss forums between 2012 and 2026, the convention is a daily scalp serum somewhere around 0.05% to 0.2%. It is usually blended with GHK-Cu and often applied under minoxidil rather than instead of it.

How long does AHK-Cu take to work?

No trial has measured that, in any species. The only study ran in a dish and on excised tissue, over days. It reported follicle elongation, not anything a person would see in a mirror.

As reported, users describe three to six months before claiming a change. That is roughly one hair cycle, and roughly the window in which regression to the mean does its own work.

Is AHK-Cu the same as GHK-Cu?

No. One residue differs: alanine where GHK-Cu has glycine. They chelate copper through similar chemistry, which is why the marketing treats them as interchangeable, and why the evidence does not.

GHK-Cu has three randomised human trials across forty years, two of them negative. AHK-Cu has one indexed primary study, in organ culture. Borrowing a cousin's literature is the single most common error made about this compound.

References

Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PMID 17703734
Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex in rat experimental wounds. J Clin Invest. 1993. PMID 8227353
Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex. FEBS Lett. 1988. PMID 3169264
Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med. 2026. PMID 41924746
Li H, et al. Microneedle-mediated delivery of copper peptide through skin. Pharm Res. 2015. PMID 25690343
Hureau C, et al. X-ray and solution structures of Cu[II] GHK and Cu[II] DAHK complexes: influence on their redox properties. Chemistry. 2011. PMID 21780203
Philips N, et al. Stimulation of cell proliferation and expression of matrix metalloproteinase-1 and interleukin-8 genes in dermal fibroblasts by copper. Connect Tissue Res. 2010. PMID 20053132
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171
Li H, et al. Selected biomarkers revealed potential skin toxicity caused by certain copper compounds. Sci Rep. 2016. PMID 27892491
FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov
World Anti-Doping Agency. The Prohibited List, section S0 Non-Approved Substances. wada-ama.org
Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts. 2025. PMID 39963574

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.